FDA Approves GSK Diabetes Combination Therapy
Posted on: Thursday, 2 February 2006, 21:01 CST
The FDA has approved GlaxoSmithKline's combination product, Avandaryl, for the treatment of type 2 diabetes.
Avandaryl combines Avandia and Amaryl, two other diabetes drugs for the control of blood sugar levels. As an adjunct to diet and exercise, Avandaryl is indicated to improve blood sugar control in patients with type 2 diabetes who are not being sufficiently.
Type 2 diabetes is characterized by high blood sugar levels that occur when the body does not produce enough insulin or does not respond properly to its own natural insulin, a condition called insulin resistance.
"Avandaryl, a combination of rosiglitazone and a sulfonylurea, provides two different, yet complementary, mechanisms of action to treat diabetes by improving blood sugar control in patients with type 2 diabetes. The patient's treatment regimen combines these two medicines into one convenient tablet," said Dr Barry Goldstein, director, division of endocrinology, diabetes and metabolic diseases, Jefferson Medical College, Philadelphia.
Source: Datamonitor
Related Articles
- Low Blood Sugar Events Increase Dementia Risk in Elderly Patients With Type 2 Diabetes, Kaiser Permanente Study Finds
- Study Links Body Clock To Diabetes And Blood Sugar
- Pink Bark Reduces Blood Sugar in Diabetics
- Diabetics' Deaths Tied to Lower Blood Sugar
- Study Links Blood Sugar to Newborn Risks
- Landmark Study Shows Avandia(R) (Rosiglitazone Maleate) Is More Effective Than Metformin or a Sulfonylurea in Long-Term Blood Sugar Control in Type 2 Diabetes
- Diabetics Getting Better at Controlling Their Blood Sugar
- Blood-Sugar Control Prevents Heart Disease 'Landmark Study' Solves Diabetes Riddle
- Diabetics' Blood Sugar Control and Cholesterol Levels Dramatically Improved By NAMCP Diabetes Patient Report Card(R) and a Web-Based Education Program
- Type 2 Diabetics Battle Blood Sugar Woes
 |
 |
User Comments (0)
RSS Feeds